Overview

A Phase 1b, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures

Status:
NOT_YET_RECRUITING

Trial end date:
2027-11-29

Target enrollment:

Participant gender:

Summary

Cannabidiol oral solution (CBD-OS) is approved in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or Tuberous sclerosis complex (TSC) in patients 1 year of age and older. This study will assess the efficacy and safety of CBD-OS in participants aged 12 to 75 years for the treatment of focal-onset seizures (FOS).

Phase:

PHASE1

Details

Lead Sponsor:

Jazz Pharmaceuticals

Collaborator:

Jazz Pharmaceuticals Research UK Ltd.